Question explored with the scientific record
how many died in active arm of mana flu vaccine study
No retrieved study named "mana flu" or reported deaths by study arm for any influenza vaccine trial.
The evidence you provided contains no study called "mana flu" and no trial that reports how many people died in the active (vaccine) arm versus the control arm. The closest match is a 2000 cohort study of elderly nursing-home residents in Japan [1]. That study compared vaccinated to unvaccinated people, not a blinded trial with an active arm. It reported fewer deaths in the vaccinated group (0.009% vs 0.043%), but those are population rates, not trial-arm counts [1].
A 2018 cluster-randomized trial of adjuvanted vs standard flu vaccine in nursing homes reported all-cause mortality: 18.2% in the aTIV-offer homes vs 17.5% in the TIV-offer homes, a difference that was not statistically significant (HR 1.05, 95% CI 0.99–1.11) [2]. That is the closest you get to a per-arm death count, and it still does not answer your question because the trial compared two vaccines, not vaccine vs placebo, and the "mana flu" name does not appear.
The remaining records cover splenectomy complications, pandemic H1N1 epidemiology, metformin, COVID-19 cardiovascular outcomes, and vaccine procurement law [3, 4]. None of them report a "mana flu" study or any influenza vaccine trial with active-arm death counts.
My call: the question cannot be answered from the retrieved evidence. No study matching the name "mana flu" was found, and no influenza vaccine trial in this set reports how many died in the active arm. Confidence: not clear — the retrieval simply did not contain the study you are asking about.
Sources used 4
-
Vaccine effectiveness for influenza in the elderly in welfare nursing homes during an influenza A (H3N2) epidemic
In a 1998-99 cohort of 22,462 elderly nursing-home residents during an influenza A (H3N2) epidemic, influenza vaccination was associated with significantly fewer influenza illnesses, hospitalizations, and deaths and with no serious adverse reactions.
DOI: 10.1017/s0950268899004410 -
994. AS03-Adjuvanted H5N1 Avian Influenza Vaccine Modulates Early Innate Immune Signatures in Peripheral Blood Mononuclear Cells
In a cluster-randomized trial, offering aTIV versus TIV reduced all-cause hospitalization among long-stay nursing home residents (HR 0.94, 95% CI 0.88-0.99), though post-hoc race adjustment attenuated the estimate.
DOI: 10.1093/ofid/ofy210.831 -
Post-Splenectomy Complications and Outcomes: A Retrospective Cohort Study
In a retrospective Iranian cohort of 174 splenectomy patients, infectious and thromboembolic complications were common and OPSI carried high mortality, with no clear advantage of open versus laparoscopic approaches, underscoring vaccination and anticoagulation for risk mitigatio…
DOI: 10.32592/smmr.202501.02.03 -
Prevalence of side-effects associated with the booster dose of Pfizer-BioNTech (BNT162b2) of COVID-19 Vaccine among vaccinated adults in the Eastern province of Saudi Arabia
A retrospective cross-sectional study in the Eastern Province of Saudi Arabia assessing short-term side-effects after the Pfizer-BioNTech booster (BNT162b2) in adults, finding that about 95% reported at least one adverse event—mostly mild and short-lived—with comorbidity status …
DOI: 10.1016/j.infpip.2022.100251